NewsBenzingaBarclays mantiene la recomendación de sobreponderar sobre West Pharmaceutical Services y eleva el precio objetivo a 500 dólares Barclays mantiene la recomendación de sobreponderar sobre West Pharmaceutical Services y eleva el precio objetivo a 500 dólares Benzinga 2026.10.30 15:22 (GMT+0) Open on Benzinga Other news RBC Capital Maintains Outperform on Stryker, Lowers Price Target to $375 RBC Capital Maintains Outperform on Silgan Hldgs, Raises Price Target to $48 BNP Paribas Maintains Outperform on Mondelez International, Raises Price Target to $72 Rivian Stock Gains Despite Bearish Technicals, Earnings and Autonomy Impress Deadly Blast Hit Intel’s Factory — And It Has a Hidden Bill That Nobody Can Yet Calculate Newell Brands Sees Sales Recovery Gaining Steam, But Inflation And Debt Remain Challenges
